Bruce Booth (@LifeSciVC) header
Bruce Booth (@LifeSciVC) profile picture

Early stage biotech VC. Recovering scientist. Opinions expressed are solely my own and do not express the views or opinions of Atlas Venture.

Cambridge, MA
Joined December 2010
Photo by Bruce Booth (@LifeSciVC)Photo by Bruce Booth (@LifeSciVC)Photo by Bruce Booth (@LifeSciVC)Photo by Bruce Booth (@LifeSciVC)Photo by Bruce Booth (@LifeSciVC)Photo by Bruce Booth (@LifeSciVC)Photo by Bruce Booth (@LifeSciVC)Photo by Bruce Booth (@LifeSciVC)Photo by Bruce Booth (@LifeSciVC)Photo by Bruce Booth (@LifeSciVC)
Agree with @SamDavisBio that @AnthropicAI is pitching itself as a Life Science company. Raises the big question: if it is indeed a "life science company", what % of their market value do you think they should spend on life science innovation (e.g, R&D, BD for IPRD)? Top 10 Pharma in aggregate spend $120B on R&D annually, with about $4T in market cap, or ~3%. If life science innovation is indeed their priority (and key to making disease a relic of the past), will Anthropic spend close to 3%, or $45B, on life science investments over next 12 months? That's the question. Follow the money and you'll find the priorities.
Replying to @AnthropicAI
@AnthropicAI is a life sciences company. It's literally in the second sentence of the first paragraph of their IPO deck.
9
11
1
82
11,943
The new John Galt.... Who is Chad Whitlow?
I have sadly betrayed the puffy vest community... This post made me laugh out loud... well done to "Chad Whitlow, Founder and CEO, Vestibule AI" I'm zipping my vest up right now. inpreparation.substack.com/p…
8
3,583
I have sadly betrayed the puffy vest community... This post made me laugh out loud... well done to "Chad Whitlow, Founder and CEO, Vestibule AI" I'm zipping my vest up right now. inpreparation.substack.com/p…
9
12
7
96
20,373
Both Hengrui and Isomorphic now have ~$50B valuations. One is China's largest innovative biopharma player, one is bio AI's largest... Which one will have more impact on human disease over the next 10 years? Which one will drive the biggest R&D Productivity improvements? Hengrui has 34 branded approved drugs, 100+ drugs in its clinical pipeline and 400+ ongoing clinical trials - and $4B in revenues. Isomorphic has its Drug Design Engine, that goes way beyond AlphaFold as a first-principles AI drug R&D architecture, and It has yet to put it's lead program into clinical testing, but is expected to in 2027 with many more after that... Both have lots of global partners. Both have tons of cash to invest. Both have enormous ambitions. Which one will deliver the most for patients and the ecosystem by 2036? China vs AI. Predator vs Alien. Godzilla vs Kong. The great "battle" of our time...
29
31
7
231
47,752
For diseases to be “relics of the past” in 10 years… since clinical development timelines are 8-10 years… the drugs entering development right now need to be the ones curing everything… I’m a biotech optimist, but that feels unlikely. I do appreciate the value of conveying excitement about new technologies and their possible impact, but the trough of disillusionment after over-hyped expectations is often a deep dark place for investors and innovators alike.
31
15
6
210
16,087
Impact of COINS Act on Biotech: this is the summary image, and its spot-on:
Having waded through 163 pages of the draft COINS rule published by Treasury, my team and I can now respond with a simple graphic. It will blind US companies and undermine our biopharma capabilities and national security, exactly opposite to what the policy is aiming to achieve. It does nothing to actually block a Chinese biotech from commercializing a drug in the US, with a European partner, European investors, or on its own. We value medicines highly and will now be paying others for them. Why would we do this to ourselves? We shouldn’t. But you can’t submit a comic to Treasury so we wrote out a detailed comment that both lays out how the draft rule would backfire on American biotech and what revisions would allow Treasury to better achieve their stated national security objectives. Have a look. Biotech investors and executives are welcome to sign onto our comment but the main purpose of publishing it now is to drive discussion that helps everyone sharpen their thinking and informs their own comment to Treasury, due Dec 7th. Anyone is welcome to crib from this. No need to ask. We wrote it after considerable input from legal experts and peers. Since coins draft rule is itself unclear on many points, reasonable people can disagree as to its intent and meaning, so some of our comments address broader points meant to encompass a range of possibilities. If you read what Treasury wrote, you might get the sense that they know this will backfire on America and are looking for support to revise their language to avert harm. So give this thought and submit your own analysis. We provide links in the article to the submission page. And thanks to all who have already signed on. @NPLB_org racap.com/rapport/comment-fr…
8
3
3
47
10,441
I'm a few weeks late, but our "Biotech Bait & Boats 2026" fishing season is over in the Boston Hahbah. We had tight lines, great catches, and superb biotech discussions while out on the water. We did a few dozen outings, 50+ guests, and lots of striped bass in the boat... Biotech is all about reeling in the big one!
5
4
1
45
6,515
Fun engagement on this crazy thought experiment. Might be hard to do this kind of big M&A productively, but looking fwd to seeing (if) the frontier labs move boldly in the life sciences
It's Halloween. Here's a trick-or-treat "thought experiment" for Anthropic (or OpenAI) going big into the Life Sciences. Probably more trick, than treat, but here goes... Both have made making medicines a top priority, as described in Anthropic's S1.  Right now they are taking some “small” bets in the space (~0.1% of expected market cap's).  These are welcome moves and we are hopeful for more engagement in #biotech in general from the frontier lab companies. But if you are a $2T public company (as they are likely to be post-IPO), how could you achieve scale in this life science domain?  What’s the best way for maximum impact on bringing drugs to patients? [assuming that's the goal for their efforts in the life science] I’d argue it's buying a large Pharma company and then radically changing the operating model to put compute and integration in the center. Sort of like retrofitting a big Pharma R&D enterprise into a @NimbusTx model on steroids with compute and tech integration in the center, intercolated with deep biology and drug hunting capabilities, with operational execution on the periphery (impt, but not the driver). Own the learning loops, compress the DMTA cycle across a huge portfolio. Nucleate and empower teams around great potential medicines in a decentralized R&D model... Let me get vaguely specific, for illustrative purposes. Anthropic could buy $BMY for less than 10% of its market cap, an all-stock deal. BMS has about 30,000 people.  Trim commercial (a distraction to the radical change mission) by selling the long list of tail products (top 5 products are 70% of revenues). Then apply frontier AI models to the business across the board - commercial, manufacturing, and R&D. Tons of data sits in these silos. With data, figure out where the bloat is in the corporate bureaucracy and remove it. Be especially aggressive on scaling back G&A and the lawyers, replacing headcount in those functions with AI-enablement.  In the business functions, allow change-makers to focus on operational efficiency. In R&D, BMS has about 3000 scientists/clinicians and operators on their R&D team.  Keep or even grow this group - its where the magic has to start. BMS has a legacy of great R&D advances and has tons of historical data.  Frankly, they probably have some of the deepest datasets on mAb discovery (Mederex mouse one of the most prolific mAb platforms ever), induced proximity (CelMod and related datasets are without peer), cell therapy (Juno was a pioneer with one of largest CART datasets), radiopharma (more recently), and so much more. Deeply mine these datasets. Take all the "me-too" R&D spend on crowded targets and dial it out of the portfolio...  Refocus all that energy on building deep biology datasets to complement the historical modality data. Invest in deep cell and tissue profiling, all the ‘omics, at scale and in an integrated way.  Put AI into the center of the operational workflow as an enabling tool for drug hunters, not replacing them. Work on fewer projects as a whole, but focus on “holy grail” drug targets and first-in-class/first-in-modality programs aiming for step-changes in treatment. And let AI operational efficiency compress clinical timelines as much as possible (10-20%). Unleash teams of drug hunters with AI-powered R&D at scale on any/all therapeutic areas, not restricted to where commercial wants you to focus.  A true science-first enterprise at scale.  “A great medicine makes a commercial franchise, a commercial franchise doesn’t make great medicines” rings true to me here. Commercial voices, I'm told, dominate at BMS, even back in R&D. Maybe that's not optimal? This would be a radical overhaul of a large R&D-intensive company.  Give the experiment 5-7 years to alter the vector of R&D output.  Long enough to see discovery-led changes percolate into early development and clinical PoC... This kind of ongoing R&D investment would be tiny fraction of Anthropic’s revenues during that period, offset in part by the profits from the big commercial brands.  A rounding error for them, but if it worked, this would fundamentally alter the industry’s trajectory. Probably can’t be done - changing large legacy groups is hard - but seems like the only near-term way to truly test “AI at scale in drug R&D” is thru something audacious like this, rather than just thru small (and beautiful) case studies of program-focused biotech … With $5T+ of anticipated market cap between the handful of frontier lab companies, this seems like a relatively small bet on a big prize. And, lastly, make @Prof_Oak_ head of the BMS business unit of $ANT. Trick or treat? Boo!!
7
2
30
10,099
It's Halloween. Here's a trick-or-treat "thought experiment" for Anthropic (or OpenAI) going big into the Life Sciences. Probably more trick, than treat, but here goes... Both have made making medicines a top priority, as described in Anthropic's S1.  Right now they are taking some “small” bets in the space (~0.1% of expected market cap's).  These are welcome moves and we are hopeful for more engagement in #biotech in general from the frontier lab companies. But if you are a $2T public company (as they are likely to be post-IPO), how could you achieve scale in this life science domain?  What’s the best way for maximum impact on bringing drugs to patients? [assuming that's the goal for their efforts in the life science] I’d argue it's buying a large Pharma company and then radically changing the operating model to put compute and integration in the center. Sort of like retrofitting a big Pharma R&D enterprise into a @NimbusTx model on steroids with compute and tech integration in the center, intercolated with deep biology and drug hunting capabilities, with operational execution on the periphery (impt, but not the driver). Own the learning loops, compress the DMTA cycle across a huge portfolio. Nucleate and empower teams around great potential medicines in a decentralized R&D model... Let me get vaguely specific, for illustrative purposes. Anthropic could buy $BMY for less than 10% of its market cap, an all-stock deal. BMS has about 30,000 people.  Trim commercial (a distraction to the radical change mission) by selling the long list of tail products (top 5 products are 70% of revenues). Then apply frontier AI models to the business across the board - commercial, manufacturing, and R&D. Tons of data sits in these silos. With data, figure out where the bloat is in the corporate bureaucracy and remove it. Be especially aggressive on scaling back G&A and the lawyers, replacing headcount in those functions with AI-enablement.  In the business functions, allow change-makers to focus on operational efficiency. In R&D, BMS has about 3000 scientists/clinicians and operators on their R&D team.  Keep or even grow this group - its where the magic has to start. BMS has a legacy of great R&D advances and has tons of historical data.  Frankly, they probably have some of the deepest datasets on mAb discovery (Mederex mouse one of the most prolific mAb platforms ever), induced proximity (CelMod and related datasets are without peer), cell therapy (Juno was a pioneer with one of largest CART datasets), radiopharma (more recently), and so much more. Deeply mine these datasets. Take all the "me-too" R&D spend on crowded targets and dial it out of the portfolio...  Refocus all that energy on building deep biology datasets to complement the historical modality data. Invest in deep cell and tissue profiling, all the ‘omics, at scale and in an integrated way.  Put AI into the center of the operational workflow as an enabling tool for drug hunters, not replacing them. Work on fewer projects as a whole, but focus on “holy grail” drug targets and first-in-class/first-in-modality programs aiming for step-changes in treatment. And let AI operational efficiency compress clinical timelines as much as possible (10-20%). Unleash teams of drug hunters with AI-powered R&D at scale on any/all therapeutic areas, not restricted to where commercial wants you to focus.  A true science-first enterprise at scale.  “A great medicine makes a commercial franchise, a commercial franchise doesn’t make great medicines” rings true to me here. Commercial voices, I'm told, dominate at BMS, even back in R&D. Maybe that's not optimal? This would be a radical overhaul of a large R&D-intensive company.  Give the experiment 5-7 years to alter the vector of R&D output.  Long enough to see discovery-led changes percolate into early development and clinical PoC... This kind of ongoing R&D investment would be tiny fraction of Anthropic’s revenues during that period, offset in part by the profits from the big commercial brands.  A rounding error for them, but if it worked, this would fundamentally alter the industry’s trajectory. Probably can’t be done - changing large legacy groups is hard - but seems like the only near-term way to truly test “AI at scale in drug R&D” is thru something audacious like this, rather than just thru small (and beautiful) case studies of program-focused biotech … With $5T+ of anticipated market cap between the handful of frontier lab companies, this seems like a relatively small bet on a big prize. And, lastly, make @Prof_Oak_ head of the BMS business unit of $ANT. Trick or treat? Boo!!
67
27
23
322
86,839
.@JasonPaulRhodes is spot on here 👇 Leaders of successful virtual biotechs, like @Prof_Oak_ , are able to bring great teams together to deliver the mission, and the best do it with the leanest possible capital efficiency required to meet the goal.
On Mithril, AI, biotech venture capital...a few (more) thoughts. First, big congratulations again to Cody @Prof_Oak_, who's terrific and keeps hitting it out of the park. He's been a vital colleague at @atlasventure And big congratulations to @AnthropicAI on the acquisition and bringing Cody on board. Mithril is a story about an intriguing new pharmacologic mechanism, a virtual team with deep disease biology expertise and killer track records in new therapeutic modalities, and AI for operational efficiency. If I had to reduce the secret of success to one thing, in biotech and in life more broadly, it would be to surround yourself with great, great people. Great biotechs pull the right people together for a common purpose, whether employees, consultants, advisors, or at CROs. Our companies have all of them along with all of the people and resources at Atlas that lean in, push, pull, sweat, and strive to build them. Capital intensity and speed are critical issues in biotech. Anything that reduces the first and increase the latter with rigor is a good thing, including the clever application of AI to orchestrate teams of remarkable, real people.
3
4
43
8,136
The Fruits of AI Drug Abundance: Indigestion In The Near Term While the long term impact of AI is likely transformational, in the near term more drugs against known targets will likely exacerbate the crowding challenge dragging down industry R&D productivity lifescivc.com/2026/10/the-fr…
23
53
34
304
82,149
Another incredible quarter from the @KymeraTx team: KT-579 - first in human data for the first ever IRF5 directed investigational medicine showing: - complete degradation of IRF5 - placebo-like safety - deep inhibition of inflammatory cytokines, interferon signaling and B-cell markers - onto a Lupus Ph1b study now KT-621 - completed last patient last visit in Broaden2, our global Ph2b AD study, with data before year end. - more details on our call.. Thanks to our amazing team, patients and partners!
Today we shared our third quarter 2026 financial results and reported positive data from the Phase 1 healthy volunteer trial of KT-579, our investigational, first-in-class, oral IRF5 degrader. Join our video webcast today to learn more about this novel program and how we’re advancing an industry-leading pipeline of oral medicines in immunology with the potential to transform patients’ lives: bit.ly/4koh5U1 #RevolutionizingImmunology
3
2
37
5,266
Bruce Booth retweeted
As someone who has helped companies pioneering the use of AI for drug discovery, this is BS. Sure, AI is a tool that we all should deploy to the best of our abilities, but the idea that AI is going to unveil new medicines at a stunning rate the way it will upend cinema, video games, financial services, advertising, gambling, etc., is a bit absurd. New medicine discovery will be one of the laggards in terms of AI revolution. Healthcare provision, diagnostics, and paperwork streamlining will all move ahead faster. Biology will continue to eat everything, AI included.
Anthropic's S-1 is out Its first highlighted potential use of AI: "profoundly accelerate the rate of progress in biology and medicine, potentially curing diseases that have plagued humanity for millennia ..." sec.gov/Archives/edgar/data/…
9
22
3
148
15,667
Great to see our Vigil Therapeutics TREM2 agonist in Science Translational Medicine! Preclinical and first-in-human evaluation of VG-3927/SAR448851, an oral small-molecule TREM2 agonist for Alzheimer’s disease science.org/doi/10.1126/scit…
4
4
45
6,670
Very apt metaphor from Gline: "Biotech is a wood chipper that is built to ingest souls and shred them..."
If you care about biotech and drug development watch this interview with Matt Gline, the CEO of Roivant, a biotech firm that is now worth $24 billion. He talks about why he thinks predictions about AI from people like Anthropic’s Dario Amodei are overly optimistic. “If Dario is right and I'm wrong, and he cures every disease in five years, man, are we all the winners from that outcome,” Gline said. “I think if you work in this industry, it is very hard not to be skeptical of any of those claims. Because, and I've said this in other settings recently too, biotech is a wood chipper that like is built to like ingest souls and shred them. It's just like such a hard business that like someone comes and they're like, oh, but I've built a computer and I'm going to push a button and all of that goes away and it just works. Like that is probably not the way that's going to go.”
8
15
3
207
28,506
We’re happy to announce John O’Malley, M.D., Ph.D., as CMO. John’s deep immunology expertise spans academic research, clinical practice, and leadership roles at CRISPR Therapeutics, Sanofi, and Brigham and Women’s Hospital. Welcome to the team, John! bit.ly/4s3R6D6
1
1
1
1,407
Fun bit of biotech history. BMS acquired Amira in 2011 for $325M upfront for it's lead program against LPA1 for fibrosis. Amira was a "smart chemistry" play founded in 2005, backed by Versant with former Merck founders, including Peppi Prasit. That drug (BMS-986020/AM152) ended up seeing efficacy in Phase 2, but was terminated for hepatobiliary toxicity in 2018. BMS scientists went back to discovery, armed with SAR from the first gen, and retooled to make admilparant... and here we are nearly a decade later with Phase 3 data. LPA1 has been a well-credentialed fibrosis target for ages, and today's topline Ph 3 hit is the culmination of a continuous discovery and development campaign against LPA1 spanning over 20 years. Drug R&D requires playing a very long game.
12
17
201
22,544